Iron Restriction to Clinical Isolates of Candida albicans by the Novel Chelator DIBI Inhibits Growth and Increases Sensitivity to Azoles In Vitro and In Vivo in a Murine Model of Experimental Vaginitis
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Candida albicans is an important opportunistic pathogen causing various human infections that are often treated with azole antifungals. The U.S. CDC now regards developing candidal antifungal resistance as a threat, creating a need for new and more effective antifungal treatments. Iron is an essential nutrient for all living cells, and there is growing evidence that interference with iron homeostasis of C. albicans can improve its response to antifungals. This study was aimed at establishing whether withholding iron by currently used medical iron chelators and the novel chelator DIBI could restrict growth and also enhance the activity of azoles against clinical isolates of C. albicans. DIBI, but not deferoxamine or deferiprone, inhibited the growth of C. albicans at relatively low concentrations in vitro, and this inhibition was reversed by iron addition. DIBI in combination with various azoles demonstrated stronger growth inhibition than the azoles alone and greatly prolonged the inhibition of cell multiplication. In addition, the administration of DIBI along with fluconazole (FLC) to mice inoculated with an FLC-sensitive isolate in a model of experimental C. albicans vaginitis showed a markedly improved clearance of infection. These results suggest that iron chelation by DIBI has the potential to enhance azole efficacy for the treatment of candidiasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Modulation of iron levels alters C. albicans dissemination, infection severity, membrane ergosterol levels, and host immune response (largely mediated by iron-induced changes in the levels of immunogenic glucans in the cell wall) (22–25).”
From Candida albicans enhances iron uptake to maintain fluconazole resistance (2025) · cites this paper as [23]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“are commonly associated with health care-associated infections in the United States as well as worldwide (1).”
BackgroundSynergy, antagonism, and what the chequerboard puts between them
Odds, F. C. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg301 · Cited by 2,481
Sobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
An integrated model of the recognition of Candida albicans by the innate immune system
Netea, M. G., Brown, G. D., Kullberg, B. J., & Gow, N. A. R. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1815 · Cited by 946 · cited 1×
“It is becoming increasingly clear that the innate immune response is an important host defense against Candida infection (13), with iron availability and sequestration being important components of susceptibility and immunity (14–16).”
BackgroundThe Battle for Iron between Bacterial Pathogens and Their Vertebrate Hosts
Skaar, E. P. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000949 · Cited by 796
Iron availability and infection
Weinberg, E. D. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.07.002 · Cited by 516
Pfaller, M. A., & Diekema, D. J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00937-12 · Cited by 484
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 389 · cited 1×
“Additionally, FLC administered orally is highly bioavailable rapidly 204 entering the systemic circulation for delivery to tissues including into vaginal secretions but with 205 >60% of the FLC load being eliminated non-metabolized and intact via urinary excretion (41).”
BackgroundEpidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376 · cited 1×
“predisposing host factors are implicated in infection (12).”
Background
Research works printed but not linked: 2
- Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard—3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
- Clinical and Laboratory Standards Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts; 4th informational supplement. CLSI document M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA.
Cited by
Fungal Lanosterol 14α-demethylase: A target for next-generation antifungal design
Monk, B. C., Sagatova, A. A., Hosseini, P., Ruma, Y. N., Wilson, R. K., & Keniya, M. V. (2019) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2019.02.008 · Cited by 164
Sheng, M. M., Jia, H. K., Zhang, G. Y., Zeng, L. N., Zhang, T. T., Long, Y. H., Lan, J. Q., Hu, Z. Q., Zeng, Z., Wang, B., et al. (2020) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1910.10066 · Cited by 88
Jin, X., Zhang, M., Lu, J., Duan, X., Chen, J., Liu, Y., Chang, W., & Lou, H. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.06.016 · Cited by 75
Iron‐MOFs for Biomedical Applications
Yu, Z., Lepoitevin, M., & Serre, C. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202402630 · Cited by 73
Tripathi, A., Liverani, E., Tsygankov, A. Y., & Puri, S. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013413 · Cited by 56
Metadata
- Authors
- Savage, K. A., Parquet, M. D. C., Allan, D. S., Davidson, R. J., Holbein, B. E., Lilly, E. A., & Fidel, P. L.
- Affiliations
- Chelation Partners Inc., Halifax, Nova Scotia, Canada
- Dalhousie University (CA)
- Louisiana State University (US)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2018-08
- Volume
- 62
- Issue
- 8
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC6105849
- OpenAlex
- W2807244885
- Cited by
- 53
- References
- 48
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 5 · 2023: 7 · 2022: 7 · 2021: 5 · 2020: 8 · 2019: 9 · 2018: 3
- FWCI
- 4.73
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-01-29)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Government of Canada
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida albicans, iron chelation, iron limitation, fluconazole, candidiasis, vaginal candidiasis, antifungal resistance, iron homeostasis, deferoxamine, deferiprone, combination antifungal therapy, mouse infection model
- MeSH terms
- Deferiprone, Animals, Antifungal Agents, Azoles, Candida, Candida albicans, Deferoxamine, Disease Models, Animal, Drug Synergism, Female, Vaginitis, Drug Resistance, Fungal, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Iron Restriction to Clinical Isolates of Candida albicans by the Novel Chelator DIBI Inhibits Growth and Increases Sensitivity to Azoles In Vitro and In Vivo in a Murine Model of Experimental Vaginitis. https://app.cochat.ai/papers/10.1128/aac.02576-17
- The paper
- Savage, K. A., Parquet, M. D. C., Allan, D. S., Davidson, R. J., Holbein, B. E., Lilly, E. A., & Fidel, P. L. (2018). Iron Restriction to Clinical Isolates of Candida albicans by the Novel Chelator DIBI Inhibits Growth and Increases Sensitivity to Azoles In Vitro and In Vivo in a Murine Model of Experimental Vaginitis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.02576-17
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.